Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare...

Related Keywords

United Kingdom ,Switzerland ,Great Britain ,Alan Sandler ,Healthcare Products Regulatory Agency ,Facebook ,Twitter ,Exchange Commission ,Prnewswire Mirati Therapeutics Inc ,Mirati Therapeutics Inc ,Bristol Myers Squibb Company ,Mirati Therapeutic Inc ,Nasdaq ,Linkedin ,University Hospital Birmingham ,Mirati Therapeutics ,Consultant Medical Oncologist ,Safety Information ,Product Characteristics ,Mirati Therapeutic ,Bristol Myers Squibb ,Therapeutic Susceptibility ,Mutant Cancers ,Mouse Models ,Brain Metastases ,Preclinical Models ,Clinical Data ,Mutant Non Small Cell Lung ,Clin Cancer ,Published April ,Markets ,